Bioengineering and biotechnology

Researchers at MIT have developed microscopic devices that “can travel autonomously through the blood and provide electrical stimulation to precise brain regions,” and could one day be used to treat brain diseases, mental illness, or other parts of the body, reports Zoe Kriegler for Medical Design & Outsourcing. The development of microscopic wireless electronic devices (SWEDs) could “eliminate the need for brain surgery in some cases, decreasing the risk to the patient and the expense of the procedure by hundreds of thousands of dollars,” Kriegler explains. 

Prof. Deblina Sarkar speaks with Forbes reporter William A. Haseltine about her work developing “circulatronics,” microscopic electronics devices that could one day be used to help treat brain diseases. “What we have developed are tiny electronic devices that can travel through body fluids and autonomously find their target regions, with no external guidance or imaging,” explains Sarkar. “They provide very precise electrical stimulation of neurons without the need for surgery.” 

Nature reporter James Mitchell Crow spotlights Prof. Leonard Guarente’s work studying the impact of calorie restriction in life expectancy. Guarente’s research points to “the importance of a set of genes and associated proteins called sirtuins.” Guarente says: “If you make them more active, you extend the lifespan.”  

Prof. Linda Griffith speaks with Science Friday host Flora Lichtman about her work studying endometriosis. “I did a lot of things in the regenerative medicine space. But I had an epiphany that there’s so many chronic and inflammatory disease that we don’t know how to treat so I started building models of human organs and tissues in the lab using what we called microfluidic chips,” Griffith explains. “When I got asked about endometriosis, it was actually a perfect application for this kind of approach because we really need to study the lesions very carefully in the lab in ways that is very hard to study in patients.” 

Prof. Deblina Sarkar speaks with Bloomberg Businessweek Daily reporters Carol Massar and David Gura about her work using microscopic technology to treat and identify health issues. We are building “tiny nanoelectronics chips which can seamlessly integrate with our body and brain,” says Sarkar. “This can diagnose disease or treat diseases which even drugs cannot fix.” 

Boston Business Journal reporter Grant Welker spotlights Biogen's groundbreaking ceremony for its new headquarters in MIT’s Kendall Common development. "This area is the most perfect place to do it, because you have some of the highest levels of ingenuity, innovation and energy around the biotech industry, and not to mention partnerships with academic excellence," said Nicole Murphy, Biogen’s executive vice president for pharmaceutical operations and technology." It was absolutely critical to why we feel we want to be here."

Earlier this week, Biogen celebrated the groundbreaking for the company’s new headquarters in MIT’s Kendall Common development, reports Catherine Carlock for The Boston Globe. “When a company as influential as Biogen breaks ground on the new global headquarters, it is an unmistakable vote of confidence — confidence in Massachusetts, confidence in Cambridge, and confidence in Kendall Square, and confidence in the future," said MIT President Sally Kornbluth. “It is on us, on us in Massachusetts, to find new ways to make sure this amazing ecosystem can maintain its record of trailblazing science and transformative treatments and cures.”

Biogen will move its headquarters to a new facility at 75 Broadway in MIT’s Kendall Common development, reports Greg Ryan and Hannah Green for the Boston Business Journal. “The lease is one of the most significant life sciences real estate transactions in Greater Boston,” they write. 

Biogen will move its headquarters to MIT’s Kendall Common development in 2028, reports Catherine Carlock and Jonathan Saltzman for The Boston Globe. “Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century,” says Governor Maura Healey. “We are thrilled to see them begin a new era in our state.”

Writing for The Boston Globe, Prof. Pierre Azoulay and Prof. Jeffrey Flier of Harvard Medical School make the case that any reforms at the NIH “should be grounded in evidence rather than tradition, avoiding the influence of special interests or political considerations.” They add that this approach “is an acknowledgement of NIH’s accomplishments and a charge to adapt it to the new realities of 21st-century science. The overarching goal must be to secure and enhance the decades-long role of the United States at the forefront of biomedical research, an outcome that the public both wants and deserves.”

WCVB-TV's Chronicle spotlights Prof. Linda Griffith, “a forerunner in the field of biological engineering,” for her research investigating endometriosis and breaking the stigma around menstruation. Griffith founded the MIT Center for Gynepathology Research in 2009 and “one of their objectives is to help develop ways of staging endometriosis, similar to how cancer is characterized.” Griffith notes that by focusing on menstruation and making it a science, “I think we will really change the game for women.

The Boston Globe’s Angelina Parrillo interviews Jasmina Aganovic ’09 about her beauty company Arcaea, which reconstructs data from extinct flowers to produce fragrances. “I viewed fragrance as this remarkable emotional storytelling category and people don’t view science as being associated with creativity, emotion, or storytelling,” Aganovic says. “I think that that’s very far from the truth.”

The Engine Ventures' CEO and Managing partner Katie Rae talks to Forbes’ Alex Knapp about its recent round of fundraising for investments in startups focused on sustainability, health and infrastructure. Rae also sees opportunities in quantum computing and other new hardware, saying “power and climate and compute all go together.” 

Katie Rae, CEO and managing partner of the Engine Ventures, speaks with Boston Globe reporter Aaron Pressman about The Engine Ventures’ third investment fund, which remains focused on “helping early-stage startups develop and commercialize ‘tough tech,’ which can include anything from fusion power generators to cement made without fossil fuels.” Rae notes: “You see this dynamism not just for climate, but for all things manufacturing, whether it’s biotech, whether it’s AI chips, it is about as an exciting moment as you could get for what we do.” 

Forbes selects innovators for the list’s Healthcare & Science category, written by senior contributor Yue Wang. On the list is MIT PhD candidate Yuzhe Yang, who studies AI and machine learning technologies capability to monitor and diagnose illnesses such as Parkinson's disease.